B. Riley raised the firm’s price target on Eton Pharmaceuticals (ETON) to $31 from $26 and keeps a Buy rating on the shares. Following a strong Q4, Eton delivered enhanced revenue visibility with FY26 guidance above $110M and more than 30% adjusted EBITDA margin, alongside long-term targets of a $200M run-rate exiting 4Q27, 50% margins by 2028, and $500M revenue by 2030, reinforcing a multi-year growth trajectory, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year
- Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M
- Is ETON a Buy, Before Earnings?
- Eton Pharmaceuticals participates in a conference call with Craig-Hallum
- Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum